Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope.

ABSTRACT: Antibodies have been widely used for cancer therapy owing to their ability to distinguish cancer cells by recognizing cancer-specific antigens. Epidermal growth factor receptor (EGFR) is a promising target for the cancer therapeutics, against which several antibody clones have been developed and brought into therapeutic use. Another antibody clone, 528, is an antagonistic anti-EGFR antibody, which has been the focus of our antibody engineering studies to develop cancer drugs. In this study, we explored the interaction of 528 with the extracellular region of EGFR (sEGFR) via binding analyses and structural studies. Dot blotting experiments with heat treated sEGFR and surface plasmon resonance binding experiments revealed that 528 recognizes the tertiary structure of sEGFR and exhibits compe

SUBMITTER: Makabe K 

PROVIDER: S-EPMC7952593 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature